Sage Therapeutics jumps to over 10-month high after Supernus Pharma's buyout offer

Supernus Pharmaceuticals

16/06/2025 15:25

Updates

** Shares of Sage Therapeutics SAGE.O gain 35.5% to $9.07

** Supernus Pharmaceuticals SUPN.O to acquire SAGE in up to $795 million deal, gaining access to Zurzuvae — the only postpartum depression pill approved in the U.S.

** Shares of SUPN rise 1.7% to $32.57

** Transaction is expected to close in the third quarter of 2025

** Supernus has offered $8.50 in cash for each share held and up to $3.50 per share in cash if certain milestones are achieved

** In January, Sage rejected a $469 million bid from Biogen BIIB.O, which co-developed Zurzuvae

** SUPN's deal appropriately contemplates the growth potential for Zurzurvae - brokerage Needham

** Including session's move, Sage shares up 67.3% YTD

 (Reporting by Sriparna Roy and Padmanabhan Ananthan in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))